CRECON MEDICAL ASSESSMENT

JP

Series

Series

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [34] Pharmacoeconomic evaluation of cancer: (2) What lies behind of NICE rejection of cancer drugs? (Colorectal cancer). Monthly Medical Information Express. 2011; 2:80-83. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [33] Pharmacoeconomic evaluation of cancer: (1)Basic information of cancer. Monthly Medical Information Express. 2010; 12:68-72. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [32] Breaf report of the ISPOR 4th Asia-Pacific Conference. Monthly Medical Information Express. 2010; 11:80-83. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [31] Pharmacoeconomic evaluation of hepatitis C. Monthly Medical Information Express. 2010; 10:70-73. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [30] Pharmacoeconomic evaluation of vaccine: (2)HPV vaccine. Monthly Medical Information Express. 2010; 9:82-85. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [29] Pharmacoeconomic evaluation of vaccine: (1) Streptococcus pneumococcal vaccine in children. Monthly Medical Information Express. 2010; 8:84-87. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [28] Pharmacoeconomic evaluation of glaucoma. Monthly Medical Information Express. 2010; 7:104-107. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [27] Pharmacoeconomic evaluation of osteoporosis. Monthly Medical Information Express. 2010; 6:98-101. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [26] The role of pharmacoeconomic evaluation after an introduction of new drug creation allowance. Monthly Medical Information Express. 2010; 5:80-83. (in Japanese)

  • Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [25] Pharmacoeconomic evaluation of rheumatoid arthritis. Monthly Medical Information Express. 2010; 4:76-79. (in Japanese)

TOPSeries
TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA